Zoetis Inc.

Capital Structure and Liquidity Zoetis maintains a debt-to-equity ratio of 2.71, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 3.03 and $2.08 billion in cash and equivalents. However, net cash is negative after subtracting total debt, signaling potential liquidity constraints. ### Profitability and Returns Zoetis generates strong returns, with a return on equity (ROE) of 80.25% and a return on assets (ROA) of 17.28%, both exceeding the median for the Pharmaceuticals industry. These metrics suggest efficient use of equity and asset base to generate profits. ### Segments and Geographic Exposure The company operates through two primary segments: the United States and International. Revenue concentration is not explicitly disclosed, but the company markets its products in approximately 45 countries, indicating a diversified geographic footprint. ### Growth Trajectory Zoetis reported FY2025 revenue of $9.47 billion, with a net income of $2.67 billion. The company's capital expenditures of $621 million reflect ongoing investment in growth and operational efficiency. Analysts project a mean price target of $147.57, with a median of $142.50, suggesting moderate growth expectations. ### Risk Factors Zoetis faces high dilution risk, with a diluted share count of 443.84 million, moderately above the basic share count of 424.93 million. The risk assessment highlights potential dilution from offerings or share repurchase programs. Additionally, the company's long-term debt of $9.04 billion poses credit risk, particularly if interest rates rise. ### Recent Events In 2022, Zoetis completed the acquisition of Jurox, an animal health company in Australia, enhancing its product portfolio and manufacturing capabilities. The company also adopted new tax disclosure guidance effective January 1, 2025, which will impact its financial reporting.